Pharmaceuticals company Supriya Lifescience announced Q1FY25 results: In the first quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 21.7 % YoY increase, reaching Rs 160.63 crore compared to Rs 132.02 crore in Q1 FY24. EBITDA for Q1 FY25 stood at Rs 62.54 crore, with an EBITDA Margin of 38.9%, as opposed to an EBITDA of Rs 44.49 crore in Q1 FY24 with an EBITDA margin of 33.7%. This marks a growth of 40.6% YoY. The Profit After Tax (PAT) for Q1 FY25 came at Rs 44.64 crore, compared to Rs 28.51 crore in Q1 FY24. The PAT Margin stood at 27.8% in Q1 FY25, compared to 21.6% in Q1 FY24. The company has seen good growth across different therapeutic areas in Q1FY25 European markets now contribute 51% of our business revenue up from 43% in Q4FY24 and 34% in Q1FY24. Saloni Wagh, Managing Director, Supriya Lifescience, commenting on the results, said, “We are engaged in discussions with a diverse range of companies, from major pharmaceutical firms to innovative enterprises, to establish partnerships for supplying tailored products. The company achieved a record capital expenditure of Rs 146 crore in the last financial year while also enhancing its return on equity by 210 basis points. We're proud to unveil our new R&D; facility at Lote Parshuram and anticipate the completion of our Ambernath lab by early Q2FY25. These state-of-the-art centers will drive our next phase of growth, focusing on advanced product development, CMO/CDMO opportunities, and expanding our portfolio to meet evolving market needs. Moving forward, the company aims for significant growth with improved profitability.” Result PDF
Conference Call with Supriya Lifescience Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.